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ABSTRACT
TELOMERASE ACTIVITY IN HUMAN PREIMPLANTATION EMBRYOS
Diane Lynne Wright 
Old Dominion University and 
Eastern Virginia Medical School, 2000 
Director: Dr. Susan E. Lanzendorf
Telomerase, a ribonucleoprotein. has been described as an essential component of 
highly proliferative cells, which stabilizes the telomeres and avoids cellular senescence. 
Telomerase has been identified in various embryonic cell stages, hematopoietic cells, and 
in >85% of tumor tissue biopsies analyzed. The ability to measure the potential to 
proliferate successfully could provide an objective measure of an embryo’s quality. The 
objectives of this study were to modify the telomeric repeat amplification protocol 
(TRAP) assay system for increased sensitivity to allow detection of telomerase activity in 
the single cell o f an oocyte and embryo, obtain telomerase activity levels for the oocyte 
through blastocyst, and finally, evaluate the use o f measuring telomerase activity within 
biopsied blastomeres to predict blastocyst development. Telomerase positive (DU-145 
and PMEF) and negative (Hs27 and Detroit 551) cell lines were used to evaluate the 
assay system followed by the use of discard and donated oocytes and embryos for the 
comparative evaluation o f telomerase activity and maturation level. Immature oocytes, 
mature oocytes, zygotes, 2-3 cell, 4-5 cell, 6-7 cell, 8-16 cell embryos, morulae, and 
blastocysts were evaluated individually for telomerase activity. Thawed zygotes cultured 
to day three were biopsied, by removing 1 -2 cells and the biopsied embryos followed 
through culture to blastocyst. Telomerase activity was detected in positive cell lines and 
none measured in negative cell lines. Analysis of 60 single DU-145 cells showed
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detectable levels o f telomerase activity in all cells. Of discard oocytes and embryos 
analyzed, 97.6% had measurable levels o f telomerase activity. Telomerase activity was 
detected in all developmental stages. Immature oocytes and blastocysts had similar 
levels of telomerase activity, however both groups had significantly higher activity than 
the zygote through pre-morula stage embryo. There was no difference in telomerase 
activity of cells biopsied from embryos that reached the blastocyst stage or those that 
arrested in growth. Human oocytes through blastocyst stage embryos express telomerase 
activity, however the level o f telomerase activity in a single blastomere of the day 3 
cleavage stage embryo was not able to predict the growth potential o f an embryo.
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Methods to evaluate accurately the quality o f an embryo remain elusive. 
Morphological measures have allowed some improvement in the ability to identify good 
embryos (potential to produce viable offspring), nevertheless, transfer of excellent quality 
embryos does not always result in a pregnancy. Preimplantation genetic evaluations have 
allowed for the deselection of genetically unsuitable embryos. Unfortunately, none of 
these techniques offer a complete picture of the embryo’s potential viability. 
Distinguishing a good quality embryo from bad, before transferring, remains more 
guesswork than science. The ability to measure the zygote’s potential to proliferate 
successfully could provide one more piece of the information. Telomerase, a 
ribonucleoprotein, has been described as an essential component of highly proliferative 
cells, which stabilizes the telomeres and avoids cellular senescence. The stability o f an 
embryo’s chromosomes is essential for successful proliferation and differentiation into 
the various tissues during development. Measuring the level of telomerase activity could 
provide information on the proliferative capability of an embryo.
Telomeres
Telomeres are located at the terminal ends o f chromosomes and have a unique 
structure of 6 bp repetitive sequences (Blackburn, 1991). In humans, the sequence is 
TTAGGG (Counter et al., 1992). Telomeres prevent nonspecific chromosomal 
recombination, allow complete replication of the chromosomal DNA without the inherent 
loss due to the DNA polymerase machinery, and help the chromosome bind to the
The model for this dissertation is Molecular Reproduction and Development
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nuclear matrix (Counter et al., 1992; Counter et al., 1994: de Lange, 1992). Telomeres 
shorten with each division o f a somatic cell, due to the inability o f DNA polymerase to 
completely replicate the end of chromosomes (Watson, 1972). Counter et al. (1992) 
established that mortal cells shortened by approximately 65 bp per generation. This 
shortening phenomenon has led to the theory that telomeres serve as a ‘mitotic clock’ for 
the cell (Allsopp et al., 1992). Human fibroblasts were found to be capable o f only a 
limited number of population doublings before they exited the cell cycle, thus limiting the 
replicating potential o f somatic cells. The researchers also established a direct correlation 
in the length o f the telomere at the start of culture and the doubling capacity.
Telomerase
In some cell types, telomerase is active and the telomeres are stabilized during 
divisions with no telomeric shortening (Morin, 1989). Germline cells (Allsopp et al.,
1992; Kim et al., 1994; Wright et al., 1996), embryonic tissues (Kim et al., 1994; Sharma 
et al., 1995; Wright et al., 1996), embryonic stem cell lines (Thomson et al., 1998), most 
tumor cells (Kim et al., 1994; Counter et al., 1994; Sharma et al., 1995), and some 
hematopoietic cells (Chiu et al., 1996; Engelhardt et al., 1997; Ogoshi et al., 1997) 
maintain telomerase activity to allow infinite divisions without disruption o f the genome. 
The critical role of telomerase was evaluated using a mouse strain lacking the telomerase 
RNA (mTR) gene (Blasco et al., 1997; Lee et al., 1998). Blasco and coworkers (1997) 
created mice that lacked the RNA component of telomerase (mTR^ ). When primary 
mouse embryonic fibroblasts (PMEF) were analyzed from generation 2 (G2), G4, and G6 
by FISH analysis o f telomeric ends, a decreasing trend was noted in the level of 
fluorescence signals with increasing generations. In the later generations, the authors
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
also noted an increase in aneuploid cells and end-to-end fusions o f  chromosomes, which 
included Robertsonian fusions. These mTR"‘ mice were capable o f  producing offspring 
through G5, but not in the sixth (Lee et al., 1998). A significant decline in fertility was 
noted at G4 and a significant decrease in germ cells was identified in G5. The 
seminiferous tubules were almost completely devoid of spermatogenesis in G6 males. In 
G6 females, almost all levels o f reproduction were affected from decreased number of 
oocytes ovulated to compromised uterine structure and function. A FISH probe for 
telomere repeats found a significant increase in the lack of 4 end signals o f chromosomes 
in the G6 mice (-58.75%) verses the wild type (-7.5%). Developing fetuses showed an 
increasing trend in neural tube defects (Herrera et al., 1999). By the fifth generation, 
30% of developing embryos experienced a failure of the neural tube to close. When the 
cells from the embryos with neural tube defects were compared to cells from embryos 
with closed neural tubes, significantly shorter telomeres were discovered. A subsequent 
publication reported an expected decrease in life span, wound healing, and response to 
hematopoietic insult, and an increase in the incidence of spontaneous malignancies in the 
latter generations o f this telomerase deficient mouse (Rudolph et al, 1999). The fact that 
abnormalities in these mTR"  mice did not become apparent, until later generations, may 
be explained by the ultra-long telomere length in mice (Kipling and Cooke, 1990). In 
humans the length varies, but averages approximately 10 kb in blood cells and in mice 
the length is highly variable from strain to strain reaching up to 150 kb (Kipling and 
Cooke, 1990). Since humans are a longer-living species with a significantly shorter 
telomeric length suggests that telomerase activity, or the lack of, may play a more critical 
role in cellular immortality and senescence than in the mouse. Some researchers propose
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that the lack of telomerase in somatic cells serves as a way of avoiding cancerous growth 
(Greiderand Blackburn, 1996).
As researchers began evaluating telomerase activity, somatic cell types were 
found to generally be lacking in telomerase activity, but “immortal” cell types presented 
activity (Counter et al., 1992). A follow-up study by Counter and coworkers (1994) 
provided the evidence that tumor cells (ovarian carcinoma) exhibited a shorter telomere 
length on average, but no loss of length through subsequent divisions was observed as 
compared to non-tumor cells. An upregulation of telomerase activity was noted in these 
ovarian carcinoma cells with shortened yet stable telomeres. A significant advance was 
made in telomerase evaluations by the development o f the PCR-based telomeric repeat 
amplification protocol (TRAP) by Kim et al. (1994). Of 100 immortal human cell types,
98 were found positive for telomerase activity and the 22 mortal cell types contained no 
detectable telomerase activity. Normal ovaries and testis were also positive for 
telomerase activity. Sharma et al. (1995) documented the loss of telomerase activity 
when immortal cell types were induced to differentiate. Murine embryonic stem cells 
(mES) and teratocaricnoma cells (F9) were induced to differentiate by the withdrawal of 
leukemia inhibitory factor (LIF) or addition o f retinoic acid (RA), respectively. The mES 
cell line showed no change in telomerase activity after 6 days, but by 12 days post LIF 
withdrawal telomerase activity was absent as the cells reached a differentiated state. A 
similar result was established with the F9 cell line. This relationship o f telomerase 
activity to highly proliferative cells was also demonstrated in a novel study using 
transfection. Telomerase-negative human somatic cells (retinal pigment epithelial cells - 
340 and BJ foreskin fibroblasts) were transfected with vectors that coded for the catalytic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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subunit o f telomerase, producing telomerase activity and extension o f life span in cells 
that would otherwise senesce after a finite number of population doublings (Bodnar et ai., 
1998).
Developmental studies in human fetal and adult somatic tissue have demonstrated 
a loss of telomerase expression with increased gestational age. Wright et al. (1996) found 
fetal lung, adrenal, muscle, skin, and liver at 16 weeks gestation positive for telomerase 
activity, while brain, kidney and bone were negative. Ulaner and Giudice (1997) 
demonstrated similar results for positive telomerase activity in the same fetal tissues 
through 21 weeks gestation, except in the brain and kidney tissues where activity dropped 
off after 16 weeks. These researchers also studied the fetal heart tissue and detected a 
loss of telomerase activity after 12 weeks gestation. Both studies showed the fetal and 
adult gonads exhibiting positive telomerase activity. Placental tissue and cultured fetal 
amniocytes were devoid of telomerase activity. All tissues were also evaluated in the 2- 
month neonate and telomerase activity was no longer detectable, excluding the gonad.
Progeria and X-linked dyskeratosis congenita (DKC) are the first two diseases to 
be associated with a failure of telomerase activity and subsequent decreased longevity.
DKC is passed on to sons o f carrier mothers. Patients experience problems with 
prolifically dividing tissues like skin and bone marrow. Researchers have established 
that DKC is the result o f a mutation in the gene encoding dyskerin (Mitchell et al., 1999). 
These investigators demonstrated a relationship between dyskerin and telomerase, 
through a co-immunoprecipitating study, showing that dyskerin can interact with the 
RNA component o f telomerase. Primary fibroblasts and lymphoblasts from affected 
males were found to express lower levels o f telomerase activity and shorter telomeres
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than the controls. Progeria is another disease that results in a shortened life span o f the 
affected individuals. Telomeres from Hutchinson-Gilford progeria patients were 
discovered to be shorter than those of matched controls, which was expected due the 
dramatically shortened life span experienced by sufferers (Allsopp et al., 1992).
All blood cellular components originate from hematopoietic progenitor cells that 
lie within the bone marrow. Various subpopulations o f hematopoietic cells were 
evaluated for their level of telomerase activity (Chiu et al., 1996). The primitive, 
quiescent, hematopoietic subset exhibited low-level expression o f telomerase activity that 
could be stimulated to increase transiently when a mixture o f cytokines was added. 
Conversely, the early progenitor subset had high levels o f telomerase activity and the 
cytokine mixture downregulated the telomerase activity. More mature hematopoietic 
cells remained unchanged in their low telomerase activity in the presence of cytokines. 
Engelhardt et al. (1997) experienced similar results with primitive human hematopoietic 
cells. When the primitive hematopoietic cells were cultured in the presence of a 
combination o f cytokines for 48-72 hours, telomerase activity was upregulated, peaked at 
1 week of culture, and declined after 3-4 weeks. The treatment o f these cells with a 
single cytokine did not produce the same level o f upregulation. Another study in the 
mouse demonstrated the same cytokine receptor associated telomerase upregulation using 
T cells isolated from the spleen (Ogoshi et al., 1997). T cells with little or no telomerase 
activity were induced to upregulate telomerase activity by exposure to the mitogens 
Concanavalin A or immobilized anti-CD3 monoclonal antibody. When these mitogens 
were added at a suboptimal level no change was noted in telomerase activity, however, 
when the cytokine IL-2 was later added telomerase activity returned. This information
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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indicates not only does stimulation of the T-cell receptor (TCR) convey an increase in 
telomerase activity, but also binding o f cytokine receptors can produce the same 
upregulation of telomerase activity. Present research suggests that telomerase activity is 
present in any cell type that has a role as a stem cell for renewing the population o f 
terminally differentiated cell types.
Gametes and Embryos
Embryos could be considered the ultimate stem cell due to an embryo’s totipotent nature 
and research has begun to explore the role o f telomerase in early embryonic development. 
A study in the rat provided information on relative levels of telomerase activity in pooled 
oocytes, 4 cell embryos and various maturity stages of male germ cells (Eisenhauer et al.,
1997), using an immortalized human embryonic kidney cell line (293) as the comparative 
control. The relative percentage values for telomerase activity, in the various oocyte 
stages on a per cell basis, were as follows: early antral was 83%, preovulatory was 159%, 
ovulated was 2%, and 4 cell embryo was 7%. Similar results were seen with the male 
germ cells. Immature spermatocytes and spermatids exhibited telomerase activity that 
was absent from mature spermatozoa. A recent study in the bovine established similar 
trends in relative telomerase activity for pooled oocytes and followed embryonic patterns 
of telomerase activity through the blastocyst stage (Betts and King, 1999). Relative 
telomerase activity was based on a comparison of telomerase activity o f the oocytes or 
embryos and a positive control cell lysate (293 cells). The researchers detected 
telomerase activity in all stages o f oocyte and embryo development. As oocytes matured, 
they noted a decrease in activity that lasted through the 8-cell stage o f embryo 
development. A dramatic 40-fold increase in telomerase activity was reported from the
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8-cell to the morula and blastocyst stage embryo.
Very few researchers have studied human gametes and embryos for telomerase 
activity. Wright et al. (1996) analyzed single mature oocytes from hysterectomy tissue 
and adult sperm samples finding that both mature gametes lacked telomerase activity. 
However, fertilized human embryos were thawed and cultured to the blastocyst stage, 
analyzed individually, and found to express very high levels of telomerase activity.
Not only does the oocyte express telomerase activity during maturation, Lavranos 
and coworkers (1999) detected telomerase activity in the granulosa cell layer of 
developing bovine ovarian follicles. Telomerase activity exhibited an inverse 
relationship to follicle size. Granulosa cells from the small preantral follicle had the 
highest level of activity and a decline was seen through increasing follicle size to 6-8 mm 
follicles. The researchers also stated that the telomerase activity in the positive control 
cell line and follicles was not related to the amount o f telomerase, but to the log of the 
amount of telomerase.
Subunits
Telomerase activity involves the concerted efforts of the RNA template 
component (TR), a catalytic subunit (TERT/TRT/EST2/TCS1/TCS), and additional 
related proteins important for the regulation of telomerase activity (TLP1/TP1, hnRNP 
Al, TRF1, TRF2). A clone of the human TR (hTR) subunit was reported in 1995 by 
Feng et al., opening the door to understanding the levels of regulation available to cellular 
expression of telomerase activity. Cloning of the RNA component defined an 
approximately 460 base length transcript with an 11 nucleotide (5’ -CUAACCCUAAC) 
template region complementary to the human telomerase sequence (TTAGGG)n. These
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researchers also found that germline tissues and tumor cell lines expressed greater levels 
of hTR than somatic tissues that lack telomerase activity. Transfecting Hela cells with 
antisense hTR resulted in death o f the cells after approximately 25 population doublings 
with telomeric DNA shortening. The results suggested an essential role for hTR in 
telomerase activity. Related work from the same laboratory (Blasco et al., 1995) 
characterized the difference between mouse and human hTR. The mouse telomerase 
RNA (mTR) subunit was found to share a 65 percent sequence homology with the human 
TR. Differentiated mouse tissues were evaluated for levels o f mTR and expression 
followed predicted levels of differentiation or immortalization. As primary Mus spretus 
fibroblasts transformed to an immortal cell line, the level o f mTR was 18 times more in 
the immortal cells than the parental cells. Detailed analysis of various prenatal, newborn 
and adult tissues revealed a down regulation o f mTR in the mouse brain, kidney, and 
lung; however, testis, intestine, liver and spleen maintained mTR expression into 
adulthood. The telomerase RNA subunit expression varies in somatic tissues o f the 
human more than in the mouse. Yashima et al. (1998) exhibited a defined decline in hTR 
expression as cells differentiated into somatic cell types, excluding testicular and adrenal 
tissue by 10 weeks postnatal development. The highest level of expression of hTR was 
undifferentiated embryonic neuroepithelium, but hTR expression was absent in the 
nervous system by the tenth week of postnatal development. Although the trend is for 
hTR expression to decrease with level of differentiation, there are examples where hTR 
transcripts are present in cells of late differentiation or lacking detectable telomerase 
activity. Yashima et al. (1998) described cells that had differentiated and were post­
mitotic still expressing hTR. A northern blot analysis study also found cell lines and
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tissue lacking telomerase activity that still expressed hTR (Avilion et al., 1996), 
suggesting that the RNA component is not a good predictor o f telomerase activity.
The most current studies suggest that the catalytic subunit (TERT) is more 
directly predictive o f telomerase activity than the RNA component (Martin-Rivera et al., 
1998; Ulaner et al., 1998). A study evaluating mouse TERT (mTERT) found a high 
correlation between mTERT expression and telomerase activity, but mTERT expression 
was independent o f mTR expression. This study employed the novel use o f a TR -/- 
strain of mouse. When the hTR gene was transfected into the mTR-/- strain, functional 
telomerase activity resumed. This was not true for the combination o f mTR and hTERT 
subunit (Beattie et al., 1998). A final discovery from this group (Martin-Rivera et al.,
1998) was the location o f mTERT and hTERT in the cell nucleus.
Regulation
The controversy over the RNA and catalytic subunits and their relationship to 
actual telomerase activity appears to be related to various regulatory mechanisms utilized 
by various tissue types. Ulaner et al. (1998) found the human fetal heart and liver to 
express hTERT and telomerase activity in a direct relationship, but the fetal kidney 
suppressed telomerase activity after the fifteenth week of gestation and continued to 
express hTERT through the twenty-first week. In addition, multiple alternative splice 
forms of hTERT were identified in these tissues consisting o f the full-length version as 
well as spliced messages containing vital deletions. With regard to the alternative splice 
forms, the fetal kidney only expresses the full-length transcript of hTERT through the 
time period of actual telomerase activity. Once the telomerase activity is gone in the fetal 
kidney, splice variants were found to be the only forms existing o f hTERT in the tissue.
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These authors suggest at least two mechanisms available within cells to regulate 
telomerase activity: at the DNA level of transcription of hTERT gene and manipulation 
at the RNA level of the hTERT transcript by alternative splicing. Human oocytes and 
embryos (Brenner et al., 1999) have also been evaluated for alternate splice variants of 
the human telomerase catalytic subunit. Oocytes and embryos were found to express 
hTERT, but there was a huge variation between various embryos and cells. The alternate 
splice forms were 430 bp, 400 bp, and 250 bp in size. Embryos tended to express all 
sizes and oocytes predominately expressed the 430 bp size.
Chromosome 3 has been shown to contain telomerase related genes. Soder et al. 
(1997) mapped the hTR gene to 3q26.3 and found increased copy number of this locus in 
97% of tumors evaluated. A tumor repressor gene has also been located on chromosome 
3 of the human. The gene is located on the p arm of the chromosome in the region 
3p !4.2-p2l. I (Tanaka et al., 1999). Other researchers had shown a narrow region on the 
p arm of chromosome 3 (3p21.3-p22 and 3p 12-21.1) could be introduced through normal 
chromosome 3 microcell transfer, into breast cancer cells and cause repression o f tumor 
cell growth (Cuthbert et al., 1999). At least one gene from this repressor region of 
chromosome 3 exhibits its activity by causing a reduction in the catalytic subunit of 
telomerase (Horikawa et al., 1998).
The proto-oncogene Myc has been identified as a transcriptional regulator of 
telomerase activity through the activity of c-Myc, the encoded protein which is known to 
be involved in the control o f cell proliferation and differentiation (Wang et al., 1998; Wu 
et al., 1998; Greenberg et al., 1999). The transduction of two normal cell lines, human 
mammary epithelial cells (HMEC) and human diploid fibroblasts (IMR-90 and WI-38),
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with HPV-16 E6 protein, which induces c-Myc expression, produced a measurable 
increase in telomerase activity within 1 passage (Wang et al., 1998). The researchers also 
identified the catalytic component o f telomerase as a target o f c-Myc. However, in the 
rat embryo fibroblast transformation assay used, TERT alone was not able to replace the 
transforming activities of c-Myc in the cells, suggesting that Myc does more within the 
cell that just its influence on TERT levels (Greenberg et al., 1999).
Some newly discovered proteins also support a fine level o f telomerase 
regulation. In the human, telomeric repeat binding factor 1 (TRF1) has been shown to 
provide a negative feedback on telomeric length (van Steensei and de Lange, 1997).
TRF 1 did not have a detectable influence on telomerase expression, but overexpression 
of TRF 1 in a telomerase positive tumor cell line resulted in a gradual shortening of 
telomeres. A similar protein has been elucidated in fission yeast called Tazlp (Cooper et 
al., 1997), exhibiting the suppressive role on telomere length. In the mouse, a protein 
with abilities to modulate telomeric length, heterogeneous nuclear ribonucleoprotein Al 
(hnRNP Al, Al), has been described (Le Branche et al., 1998). An Al deficient mouse 
strain did not exhibit a significant difference in telomerase activity to the wild type mouse 
and Al had a positive influence on telomeric lengths. Another telomeric protein, TRF2, 
is implicated in the recent discovery o f “t loop” formation at the 3 ’-end o f telomeric 
repeats (Greider, 1999; Griffith et al., 1999). The results suggest that TRF2 induces the 
single stranded 3’-end of the telomere to loop back on itself and actually bind to the 
double stranded telomere sequence. Telomerase appears to have numerous levels at 
which its activity is regulated, suggesting an important purpose for the ribonucleoprotein 
within the cell.
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Telomeric Repeat Amplification Protocol
Current methods to evaluate and measure telomerase activity originate from a 
PCR-based assay termed telomeric repeat amplification protocol (TRAP). Kim et al.
(1994) first described the use o f this assay to evaluate various human tissues, immortal 
cell lines, and cancer cells. The assay involves two major steps beginning with 
telomerase from the lysed cells adding the 6 bp repeats to the substrate primer. The 
second step utilizes PCR to amplify these telomeric additions to a level necessary to 
measure. Shortly after this publication, a kit became available commercially 
(TRAPeze®) that provided increased sensitivity and additional controls. A study 
comparing the original method to the commercial kit found that the kit decreased sample 
processing time due to a decrease from a three-step PCR cycle to a two-step cycle (Holt 
et al., 1996). The researchers concluded the TRAPeze® was superior to the original assay 
because of the improved sensitivity, quality control additions, and decreased time needed 
to run the assay.
Most o f the TRAP assays to this point relied on the use o f radioisotope labeled 
reaction products to evaluated banding patterns on the product gels. Hisatomi et al.
(1997) described the combination of TRAPeze® with fluorescent labeled products (F- 
TRAP) and the alleviation o f  radioactivity in the analysis of human liver tissue. The 
substrate (TS) primer was labeled with Cy-5 and an automated DNA sequencer (ALF 
red™: Pharmacia Biotech) was utilized to evaluate the product run on a denaturing gel. 
Subsequent to this original study, F-TRAP has been utilized to evaluate hepatocellular 
carcinoma (Wada et al., 1998; Nagao et al., 1999), pheochromocytoma (Kubota et al., 
1998), urothelial neoplasia (Ohyashiki et al., 1998), and indomethacin treatment of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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murine colon adenocarcinoma (Ogino et al., 1999).
Gene Regulation in the Early Embryo
The human oocyte, during growth and maturation, builds up stores o f essential 
organelles, mRNA, and proteins that will be necessary for the mature oocyte and early 
fertilized embryo to use until the embryonic genome can take over the synthesis of these 
vital elements (Schultz, 1999). In the human, this shift to embryonic control takes place 
at the four to eight-cell stage (Braude et al., 1988). The study showed that various 
qualitative changes occur in polypeptide levels during the four-cell to eight-cell stage and 
are dependent on transcription. A related study also demonstrated this shift to embryonic 
driven transcription at the four-cell stage. Using RT-PCR, paternal transcripts for the X- 
linked glucose-6-phosphate dehydrogenase and the Y-linked ZFY gene were first 
detected at the four-cell stage (Taylor et al., 1997). Heikinheimo et al. (1995) measured 
human cyclin B1 and beta-actin in oocytes and embryos, using RT-PCR, and 
demonstrated a dramatic increase in embryo-derived expression o f these genes at the 6- 
cell stage.
Biopsy of Human Embryos
Since the publication of a viable technique for biopsy o f human embryos 
(Handyside et al., 1989) and first pregnancies (Handyside et al., 1990), preimplantation 
genetic diagnosis (PGD) has become a common technology, offered to couples with 
genetic disorders, in over 50 assisted reproduction programs worldwide. The challenge 
of this technique is not only the ability to remove one to two cells from an embryo 
without harm, but to also correctly amplify and evaluate the DNA o f a single cell. 
Numerous studies have established the ability to remove cells from an embryo, in the
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mouse (Wilton et al., 1989) and in the human (Handyside et al., 1990; Grifo et al., 1992), 
yet the embryo experiences no deficit in its ability to grow and implant within the uterus. 
Since the original publications that evaluated the sex of the embryos to avoid sex-linked 
diseases, the repertoire of diseases that programs can test these embryos for has grown 
immensely (ESHRE PGD Consortium Steering Committee, 1999). Biopsy of the human 
embryo has moved from a research technique to an established method for preventing 
patients from terminations, or the consideration of terminations, of ongoing pregnancies.
The study of telomerase activity in gametes and embryos is in its infancy.
Although there is a wealth of information in the literature regarding telomeres, 
telomerase and cancer, little is known about the role of telomerase in the preimplantation 
embryo. Already we know that: 1) telomerase is important for normal, and abnormal, 
highly proliferative cell types, 2) telomerase activity is regulated on numerous cellular 
levels to achieve optimal telomeric lengths, and 3) cells deemed terminally differentiated 
can become immortal by restoring telomerase activity through transfection. Certainly, 
the information already published in the aging and cancer fields will speed the pursuit of 
research in reproductive biology. Human developmental studies have discovered the 
presence of telomerase activity in various tissue types at numerous fetal growth stages. 
Research has established that in the bovine, rat, and in the human blastocyst stage 
embryo, telomerase activity is present. Baseline information on telomerase activity in 
human gametes and embryos will be necessary, before research can move into the areas 
o f regulation and differentiation. As the baseline information is compiled we will begin 
to understand the role o f telomerase in another highly proliferative cell type, the embryo, 
and have an additional way to define embryonic potential for a viable pregnancy.




Telomerase is a ribonucleoprotein that provides a mechanism for the stabilization 
of telomeres on the ends of chromosomes during cellular replication. DNA Polymerase 
is unable to replicate these ends and telomerase provides the template for the 6 bp 
repeating sequence. Without telomerase, a cell has a limited number o f divisions 
possible as the telomeres shorten to a critical point at which the cell enters senescence.
Telomerase has been identified in various embryonic cell stages, hematopoietic cells, and 
in >85% of tumor tissue biopsies analyzed. These cell types have in common the need to 
elude cellular senescence and appear to use telomerase as the mechanism to stabilize the 
telomeres and attain ‘immortality’. Human blastocysts have been evaluated for the 
presence of telomerase and found to express the enzyme, where the mature human oocyte 
did not show measurable levels of telomerase activity.
The purpose of this study was to evaluate the quantitative level o f telomerase 
from the gamete to blastocyst stage. The hypothesis to be tested was that telomerase is a 
gene transcribed from the initial startup o f the embryonic genome and that individual 
embryos differ in their successful expression o f telomerase activity. Although an embryo 
has the appearance of normal morphology, it might be lacking in telomerase gene 
expression, which would not be apparent until latter divisions as the telomeres shorten. 
Results that include a comparative value for the levels will provide information on the 
embryonic genome and further studies could use this parameter to evaluate the 
mechanisms involved in signaling the transcription of telomerase. Long-term application 
of this method could be to evaluate biopsied embryos for telomerase activity and provide
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more information on the viability potential o f the embryo.
Specific Objectives
1) Demonstrate that telomerase levels are low in mature, ovulated oocytes 
and increase with continued division o f the fertilized embryo due to the transcription of 
telomerase-associated genes in the embryonic genome.
2) Establish that embryos vary in their upregulation of telomerase activity, 
providing a predictive measure of embryonic viability, through the comparative 
evaluation of biopsied embryos.
Study Design
Preliminary Cell Line Experiments
A group of cell lines were used to modify the TRAP assay for single cell 
evaluation, from the TRAPeze® kit’s defined lower-end sensitivity o f approximately 80 
cells. Four cell lines (primary mouse embryonic fibroblasts, human prostate carcinoma, 
human foreskin, human embryonic skin) and the positive control cell line, supplied with 
the kit. were used for these experiments. An initial cross-species assay was conducted 
using the mouse fibroblast and human cancer cell types, followed by an evaluation of the 
assay’s ability to detect known positive and negative cell lines. Next, a series, of ten-fold 
dilutions o f the positive control cell lysate (10,000 to 1 cell equivalents), was evaluated 
for correlation with telomerase activity detected. Finally, 60 cells, from the known 
telomerase positive human carcinoma cell line, were tested individually for the assay’s 
ability to detect telomerase activity in the single cell.
Experiment Series One - Individual Oocvtes and Embryos
Whole oocytes and embryos were assayed individually to establish the pattern of
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telomerase activity expressed from the oocyte through various embryonic cell stages. 
The following cell stages were evaluated: immature oocyte, mature oocyte, zygote, 2-3 
cell, 4-5 cell, 6-7 cell, 8-16 cell, morula, and blastocyst.
Experiment Series Two -  Blastomeres
Part A - Individual Blastomeres o f  Entire Embryos
A selected group of cleaving embryos was completely disaggregated and each 
blastomere tested for telomerase activity. This section of data served to distinguish the 
variances between embryos and blastomeres in their expression of telomerase activity. 
Part B - Biopsy and Comparative Growth Potential
Day 3 cleavage stage embryos were biopsied and 1-2 cells removed, allowing the 
remainder of the embryo to continue developing. Telomerase activity of the blastomeres 
removed was compared with the final growth stage of the biopsied embryo, to allow for 
the comparison of cleavage potential and telomerase activity levels of the biopsied 
blastomere. A statistical comparison was made between the values obtained for 
telomerase activity in the biopsied blastomeres of embryos that successfully developed to 
the blastocyst stage and those that arrested in growth prematurely.
Those embryos that reached the blastocyst stage were treated with 
immunosurgery to isolate the inner cell mass (ICM) and telomerase activity was 
measured in the ICM for comparison with telomerase activity of the previously biopsied 
blastomeres.
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CHAPTER III 
MATERIALS AND METHODS 
Materials
The sequential culture medias used came from three sources: 1) Enhance Day 
1/D3 from Conception Technologies (San Diego, CA), 2) P I/ Blast Medium from Irvine 
Scientific (Santa Ana, CA), and 3) G1.2/ G2.2 from IVF Science (Scandinavia). Earls 
Balanced Salt Solution and Synthetic Serum Substitute were obtained from Irvine 
Scientific (Santa Ana, CA) The thaw media components, acidified Tyrode’s components, 
Bovine Serum Albumin (BSA) and Dulbecco’s Phosphate Buffered Saline, were obtained 
from Sigma Chemical Company (St. Louis, MO). Other media additives, which were 
purchased from Sigma Chemical Company, included 0.25% trypsin and hyaluronidase. 
The TRAPeze® kit was purchased from the Intergen Company (Purchase, NY). The 
Long Ranger gel solution was obtained from FMC BioProducts (Rockland, ME). All 
tissue culture dishes, aerosol barrier pipet tips, borosilicate glass Pasteur pipets and Urea 
came from Fisher Scientific (Pittsburgh, PA). PCR tubes were obtained from USA 
Scientific (Ocala, FL). Taq Polymerase and Dulbecco’s Modified Eagle Medium 
(DMEM) came from Gibco / Life Technologies (Gaithersburg, MD). Fetal bovine serum 
was purchased from Hyclone (Logan, UT). Molecular weight markers (50-350 bp) were 
obtained from LI-COR (Lincoln, NE). Borosilicate glass (B 100-75-15) for 
micromanipulation pipets was obtained from Sutter Instrument Company (Novato, CA). 
Rabbit anti BeWo serum was prepared by Atlantic Antibodies (Wyndham, ME).
Standard guinea pig complement was purchased from Cedarlane Laboratories Limited 
(Hornby, Ontario)
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Equipment
Embryos requiring a programmed thaw cycle were thawed using the Planer 
KRYO 10 Series II from TS Scientific (Perkasie, PA). Polymerase Chain Reactions were 
conducted using a Thermolyne Series 669 Thermocycler (Bamstead/Thermolyne 
Corporation). Electrophoresis and densitometric analysis were conducted using the LI- 
COR 4200 DNA Sequencer (Lincoln, NE) and fluorescent banding analysis was 
performed using the Gene ImagIR Software (Version 3.55, LI-COR). Blastomere 
isolation and deposit in reaction tubes was conducted under a Nikon SMZ-10 dissecting 
microscope. Biopsy of human embryos was performed using a Nikon Diaphot inverted 
microscope (Nikon Inc., Melville, NY), equipped with 3 sets o f Narishige MO-202 
micromanipulators and Narishige MN-2 course manipulators. A PLI-188 picoinjector 
(Medical Systems, Inc., Melville, NY) was used for control of fluid in hatching and 
biopsy pipets for biopsy of blastomeres. The pipet system used to hold the embryo in 
place was managed by the use of a Narishige IM-6 microinjector. Micromanipulation 
pipets were created using a P87 Flaming/Brown Micropipette puller (Sutter Instrument 
Company, Novato, CA) and a Narashige MF-9 microforge.
Human Oocytes and Embryos 
Some of the human material used in this study was obtained from the In Vitro 
Fertilization Laboratory at the Jones Institute for Reproductive Medicine. The use of 
patient material for research was approved by the Institutional Review Board (IRB) of 
Eastern Virginia Medical School and included the following protocols:
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1) #09-05-96-0243 -  allows for the use o f abnormally fertilized human 
embryos, which cannot be used by the patients, to be used in preclinical 
research studies.
2) #07-08-93-0052 -  allows for the use o f mature and immature oocytes that 
the patients do not require for their treatment to be used for preclinical 
research studies.
3) #07-08-93-0043 -  allows the use o f fertilized embryos for preclinical 
research studies.
In addition cryopreserved zygotes were received, for the purpose of research, 
from five centers for assisted reproductive medicine; Cooper Institute for IVF (Marlton, 
NJ), Beach Center for Infertility (Virginia Beach, VA), Fertility Center of Maryland 
(Baltimore, MD), Christ Hospital (Cincinnati, OH), New Hope Center for Reproduction 
(Virginia Beach, VA). These donated cryopreserved embryos were also used under the 
IRB protocol #07-08-93-0043. All couples signed and consented to the disposition of 
their embryos.
Cell Lines
All cell lines, except mouse cells, were obtained from the American Type Culture 
Collection (ATCC - Rockville, MD). The cell lines were cultured according to 
instructions defined by the ATCC. The three cell lines from ATCC used in this study are
as follows:
DU 145 - carcinoma, prostate cancer metastasis to brain, human, epithelial like 
Hs27 - newborn foreskin, male, human, fibroblast 
Detroit 551 - female, human, skin, embryonic
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The mouse cell line (PMEF - primary mouse embryonic fibroblasts) was created 
by the homogenization of fetuses at 13 days gestation (Abbondanzo, 1993). These 
pregnancies were the result o f a cross between B6CBAF1/J females (Jackson 
Laboratories, Bar Harbor, MA) and CD I males (Charles River Laboratories, Wilmington,
MA).
Methods
Embryo and Cell Line Culture 
Human Embryo Culture
Human embryos were cultured in sequential style medias, following instructions 
provided by the manufacturers. Briefly, pronuclear stage (Day 1) embryos were placed 
in 500 (j.1 of CO2 equilibrated media under oil, which was designated for day 1-2 stage 
embryos. After 48 hours in the first stage media, embryos were moved to media 
designated for day 3 to blastocyst stage embryos. Embryos were placed in fresh medium 
every 48 hours until the final growth stage was reached or until growth had arrested for 
24 hours.
Cell Line Culture
Cell lines were cultured in DMEM supplemented with 15 % fetal bovine serum. 
The culture medium was replaced every 48 hours with pre-equilibrated medium. Passage 
of cell cultures was initiated by the removal of culture media and addition of trypsin for 1 
min followed by 3 min incubation at 37°C with trypsin removed. As cells begin to loose 
connection with culture vessel, culture media was added by pipetting over the cells. Cell 
suspensions were then counted and aliquoted for subsequent passage or lysis.
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Thaw protocols
Zygotes were thawed according to established protocols obtained from the 
corresponding donating programs. Those zygotes requiring a programmed slow thaw 
were thawed as described by Veeck et al. (1993). Another group o f embryos were 
frozen with a similar protocol, but in straws, which does not require a programmed thaw 
(Testart, 1986). Zygotes that required a one-step thaw protocol were thawed according to 
the methods described by Freedman et al. (1988).
Embryo Biopsy
Embryo biopsy was performed in 100 p.1 drops of equilibrated Earl’s Balanced 
Salts Solution with 15% Synthetic Serum Substitute with a mineral oil overlay. Two 
drops were placed on each micromanipulation dish. Only one embryo at a time was in 
the micromanipulation dish. This embryo was out o f the culture system for a maximum 
of 15 min. A second embryo would be biopsied in the other drop with the same time 
constraint after the first biopsy was complete. Once two embryos were biopsied, a new 
micromanipulation dish was prepared.
Embryo biopsy consists o f 2 parts: 1) a hole is placed in the zona pellucida 
directly in front o f the cell designated to be removed, by the use o f Acidified Tyrode’s 
solution and 2) one or 2 blastomeres are removed from the embryo through the hole in 
the zona pellucida. Embryos were biopsied when the majority o f the embryos had 
reached the 6-8 cell stage. If  an embryo was a 4 cell at biopsy, only 1 cell was removed, 
otherwise 2 blastomeres were removed for analysis.
The embryo biopsy technique was performed as described by Gibbons et al.
(1995). The embryo is held in place using a holding pipet (120 o.d., 40 i.d.), while a hole
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is placed in the zona pellucida using a hatching pipet (10 o.d.) loaded with Acidified 
Tyrodes’ solution. After the hole is made next to a blastomere exhibiting a visible 
nucleus, the biopsy pipet (40-45 o.d.) is aligned with the hole in the zona pellucida. This 
biopsy pipet is connected to the picoinjector to allow fine movement o f  fluid within the 
pipet. The biopsy pipet is preloaded with a small column o f mineral oil followed by an 
equal size column o f the Earle’s medium. Gentle suction was performed on the 
blastomere until it had separated from the embryo. The blastomere was then expelled on 
the bottom of the micromanipulation dish a safe distance from the holding pipet and 
embryo. Blastomeres were individually removed from the micromanipulation dish in a 1 
pi column of media, once the biopsy procedure was complete, and added to a micro 
centrifuge tube containing 9 pi of CHAPS lysis buffer. These sample tubes were snap 
frozen in liquid nitrogen and stored at -80°C.
Immunosureerv of Blastocysts
Immunosurgery was conducted on embryos that reached the blastocyst stage. The 
trophectoderm was removed from the blastocysts as previously described in the mouse 
(Solter and Knowles, 1975), rheusus monkey (Thomson et al., 1995), and human 
(Thomson et al., 1998). Blastocysts that had not hatched free of their zona pellucida were 
treated with acidified Tyrode’s solution and through gentle pipeting the zona pellucida 
was removed. Whole blastocysts were exposed to rabbit anti-BeWo serum followed by 
exposure to guinea pig complement. The trophectoderm cells lyse during the 
complement step and are removed from the inner cell mass by repeated pipeting through 
a finely drawn Pasteur pipet. The longest length of each ICM was measured under the 20 
X objective using an ocular micrometer.
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Telomerase Assay
The original description and use of TRAP was published by Kim et al. (1994).
This polymerase chain reaction (PCR)-based assay allows the telomerase o f the cells 
being tested to add telomeric (TTAGGGn) repeats to the 3’ end o f  the substrate 
oligonucleotide (TS) (Step 1) and these extended products are then amplified through 
PCR to allow detection (Step 2). The TRAP assay has since been modified for sensitivity 
and accuracy and a kit is commercially available (TRAPeze distributed by Intergen, Inc.) 
for easier and more reliable testing. The kit also provides a 36 bp internal amplification 
standard, a quantitation control template - TSR8, and a pellet o f telomerase positive cells 
for controls. A comparison study o f the original TRAP protocol and the TRAPeze kit 
found the kit to be a superior system (Holt, 1996).
Preparation o f  Cell Lysates
The lysing buffer was provided in the kit, CHAPS, (10 mM Tris-HCL [pH 7.5], 1 
mM MgCb, 1 mM EGTA, 0.1 mM Benzamidine, 5 mM 3-mercaptoethanol, 0.5% 
CHAPS, 10% Glycerol). The procedure for lysis of cell lines, to liberate telomerase 
components, is described in the TRAPeze kit manual. The number o f cells ranged from 1 
x 105 to 1 x 106 cells used in each lysing reaction. Cells were centrifuged to a pellet in 
micro centrifuge tubes for 6 minutes at 6,000 X G. The supernatant was removed and the 
cells snap frozen in liquid nitrogen and stored at -80°C. At thaw, 200 pi o f CHAPS was 
added to the pellet, tubes vortexed, and incubated on ice for 30 minutes. After the lysing 
period, samples were centrifuged at 12,000 X G for 20 minutes at 4°C. From the cell 
lysates, 160 pi o f the top supernatant was removed and flash frozen in liquid nitrogen.
The aliquots were then stored at -80°C.
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Individual cells from cell line suspensions were isolated in DPBS + 1% BSA. A 
single cell, plus 5 pi of media, were added to a micro centrifuge tube containing 5 pi of 
CHAPS and incubated, on ice, for 30 minutes. The cellular extract was then snap frozen 
in liquid nitrogen and stored at -80°C. After removal o f the zona pellucida with 
Acidified Tyrode’s solution, whole embryos were placed in a micro centrifuge tube with 
10 pi of media and snap frozen in liquid nitrogen, with subsequent storage at -80°C. At 
thaw, these tubes were incubated on ice for 30 minutes to allow lysis of the cells. Both 
the embryos and the individual cells were analyzed using the entire 10 pi lysate as the 
sample.
PCR Amplification
The assay was conducted in a 25 pi reaction with 5 pmol of the TS primer (5’- 
AATCCGTCGAGCAGAGTT -3’) in 20 mM Tris-HCl [pH8.3], 1.5 mM MgCl2, 63 mM 
KC1, 0.05% Tween 20, 1 mM EGTA, .05 mM each dNTP, I U Taq DNA polymerase, 
and the primer mix (which includes the reverse “RP” primer and the Kl primer and 
TSK1 template for the internal standard). All of the reaction components were provided 
in the TRAPeze kit. The TS primer from the kit was not used. A specifically labeled TS 
Primer was purchased from LI-COR to obtain the IRD800 label necessary for use with 
the LI-COR system.
The first step of the assay was incubation at 30°C to allow any telomerase within 
the cellular lysate to add telomeric repeats to the TS primer. This step was conducted for 
30 minutes in all cellular lysate samples, except the single cell and whole embryo 
samples. The single cell and whole embryo assays were incubated for 60 minutes to 
allow the lower level of telomerase to be detected.
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After the preliminary incubation, the actual PCR step was conducted. An initial 
hold at 94°C for 3 minutes preceded amplification, to stop the telomerase reaction. The 
PCR was conducted for 38 cycles o f 94°C for 30 seconds and 59°C for 30 seconds. 
Analysis o f Telomerase product
Products were diluted 5 to 1 with IR2 Stop Solution (LI-COR), heated to 93 °C for 
3 minutes and placed directly on ice. Each product was then loaded (1 pi / lane) onto a 
7% Long Ranger denaturing gel (FMC BioProducts, Rockland, ME) with 7 M urea, fitted 
to an automated, infrared, DNA sequencer (IR2 from LI-COR, Inc., Lincoln, NE) and 
electrophoresed at 45°C and 1500 V.
The fluorescent data was analyzed using the Gene Imager software (LI-COR).
Each reaction and assay includes various controls to provide the most accurate data, 
which are also provided with the TRAPeze kit. Every assay included two negative 
reactions using CHAPS lysis buffer as the sample to evaluate primer-dimer PCR artifacts 
and contamination and the Hs27 cell lysate was run to show a negative cell reaction. A 
dilution of the lysate from the positive control cell line, provided in the kit, was run in 
every assay. All reactions contained the template (TSK1) and reverse primer (K l) for an 
internal PCR amplification control that is 36 bp in size. Finally, a quantitation control 
template was run with each assay, TSR8. This control provided a standard to estimate 
the amount o f TS primers that were extended by telomerase in each extract. Each sample 
was quantified in terms o f peak band density of the fluorescence and peak area 
(integrated optical density). Using the following formulas values were obtained for total 
product generated (TPG) and relative telomerase activity (RTA):
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Measured total area of telomerase activity (50 bp. 56. 62. etc)
Measured area o f internal 36 bp control
TPG (units) = ----------------------------------------------------------------------------------------- X 100
Measured total area of telomerase activity (50 bp. 56. 62. etc) in TSR8 
Measured area of internal 36 bp control o f TSR8
Measured total area of telomerase activity (50 bp. 56. 62. etc)
Measured area o f internal 36 bp control
Measured total area of telomerase activity in Positive Control Cells 
Measured area of internal 36 bp control Positive Control Cells
Statistical Analysis
Levene’s F-test was used to test the assumption o f homogeneity o f variance, 
resulting in statistical significance (P < 0.05). We concluded that there was not 
homogeneity of variance, therefore, Dunnett T3 post hoc test was used for multiple 
comparisons and determine significant differences at P < 0.05 between mean TPG and 
RTA activities o f each growth stage in the first experiment. Variance component 
analysis was conducted with the embryo data that had all blastomeres of the embryo 
tested for telomerase activity. For the final biopsy experiment, Levene’s F-test statistic 
was used for testing of homogeneity of variance and ANOVA was used for comparison 
of the 2 groups. A two-tailed test for Pearson correlation was used to evaluate the 
relationship between ICM size and telomerase activity in the blastomeres biopsied.





The first series of testing explored the ability of the assay system to pick up 
telomerase activity, when cells contained telomerase, and the ability to find no activity in 
cells that are known to lack telomerase activity. The diluted lysates from four cell types 
were tested, which included three human and one mouse. The cell types were DU -145 
(human, prostate carcinoma), Hs27 (human, newborn foreskin), Detroit 551 (human, 
female embryonic skin) and PMEF (primary mouse embryonic fibroblasts). The positive 
control cell pellet lysate was also evaluated with each assay. A comparative evaluation 
was initially made of human and mouse cells to establish the cross species abilities o f the 
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Fig. 1. Telomerase activity in cell lysates of human and mouse cell lines. Cell lysates 
from DU-145 (human), PMEF (mouse) and the positive control cells were diluted to 500 
cell equivalents. Data represents the mean o f single samples loaded in duplicate.
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A subsequent experiment compared telomerase activity in cells from cell lines 
known to express telomerase activity and those known to lack telomerase activity (Fig.
2). In Fig. 2, not only was the presence of telomerase activity duplicated in the DU-145 
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Fig. 2. Telomerase activity in cell lysates of positive and negative cell lines. Cell 
lysates from DU-145, Fls27, PMEF, Detroit 551, and the positive control cells were 
diluted to 100 cell equivalents. Data are the means ± 1 SD of 5 samples from one assay.
A dilution series o f the positive control cell lysate was evaluated from a 1 cell 
equivalent dilution through 10,000 cells equivalent, increasing by factors of 10. A 
logarithmic increasing trend was noted in the measured telomerase activity o f the lysate 
dilutions (Fig. 3) from the 1 cell equivalent to the 10,000 cells equivalent. To evaluate 
repeatability of the gel loading and analysis system, the identical product was loaded into
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a gel 23 times and the product was measured in all 23 lanes (Fig. 4). This comparison 
was made using the portion of the formula (see methods) integrated optical density o f 
TRAP product ladder bands / integrated optical density o f short internal control band. 
The mean value was 0.7729 with a standard deviation of .06299 for these 23 lanes. One 
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Fig. 3. Telomerase activity measured in ten-fold dilutions o f the positive control cell 
lysate. Data represents the mean of single samples loaded twice in one TRAP assay.
To evaluate the ability o f the assay to detect telomerase activity in single cell 
samples, 60 individual DU -145 cells were isolated and assayed. All cells exhibited 
measurable telomerase activity, with a mean TPG o f 20.1 ± 12.2 units per sample.
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Fig. 4. Twenty-three identical loadings of a sample of positive control cell lysate 
diluted to 100 cell equivalents.
Telomerase Activity in Whole Oocytes and Embryos
A total of 167 deselect human oocytes and embryos were evaluated for telomerase 
activity. Of this study group, 22 were oocytes, 30 were zygotes, and the remaining 115 
were cleaving embryos. These embryos were received as fresh (83.7%) deselects and 
from thawed, donated (16.3%) embryos that arrested in their development. Each oocyte 
or embryo was analyzed individually. Telomerase activity was detected in 97.6 % of 
samples tested. Two methods were used to calculate telomerase activity in these 
samples, relative telomerase activity (RTA) and total product generated (TPG). When 
both methods were evaluated statistically no difference was detected in the results.
Oocytes were studied at the immature germinal vesicle (GV) stage through the 
mature metaphase II (Mil) stage. The immature oocyte study group included 10 with a 
visible GV, and 6 oocytes with no GV and no polar body that are considered metaphase I
♦  ♦
♦  ♦
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(MI) stage oocytes. Sixteen immature oocytes were tested and all had measurable 
telomerase activity. One of the six Mil oocytes tested had no detectable telomerase 
activity. The average telomerase activity measured in these immature oocytes was higher 
than the level observed in the mature oocytes, zygotes and early cleavage stage embryos. 
The data collected on embryos ranged from the zygote through blastocyst stage. The 
pronuclear status varied with these deselects embryos. A single pronucleus developed in 
9 (6.7%) o f the samples, 62 (45 .9%) exhibited the normal complement o f 2 pronuclei, 
and 64 (47.4%) o f the embryos were multipronuclear (>3). Embryos were grouped by 
cleavage stage for statistical analysis. Additionally, nine embryos that reached the 
blastocyst stage in the final experiment of this study were subjected to immunosurgery 
and the inner cell masses (ICM) of the blastocysts were also evaluated for telomerase 
activity (Fig.5).
Telomerase activity was detected in all developmental stages. There was no 
statistical difference between the mature and immature oocytes, but telomerase activity in 
the immature oocytes was statistically greater than the zygote through 8-16 cell cleavage 
stage embryo (p < 0.05). Telomerase activity in the blastocyst group was statistically 
higher (p < 0.05) than the zygote through 8-16 cell stage embryos as well, but was not 
different from the oocytes, morula, or ICM sample means.
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Fig.5. Telomerase activity in human oocytes and embryos. The samples are grouped 
by developmental stage and calculated as TPG and RTA for immature (IM) oocytes, 
mature (M) oocytes, zygotes (Z), 2-3 cell, 4-5 cell, 8-16 cell, morula (MOR), blastocyst 
(BLST), and, inner cell mass (ICM). Numbers in parentheses represent the number of 
oocytes or embryos analyzed to achieve the mean represented. Y-error bars represent 
standard error of mean TPG values only.
The same set o f whole gamete and embryo data was also analyzed on a per cell 
basis by dividing the embryo telomerase value by the cell stage (Fig. 6). Morula cell 
number was estimated at 15, inner cell mass and whole blastocyst cell number were 
estimated based on a publication by Devreker et al. (1998) at 20.7 and 64.5, respectively.
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Fig. 6. Telomerase activity in each developmental group presented on a per cell basis. 
Cleavage stage embryos were divided by their respective cell number and Y-error bar 
represents standard error o f the mean.
The telomerase activity was significantly higher in the immature oocyte (Fig. 6) 
group than all other groups (p < 0.05), excluding the mature oocyte group, which was not 
different from any o f the comparison groups. The zygotes were statistically different 
from all other groups excluding the mature oocytes. The blastocyst telomerase activity 
was significantly lower than all cleavage stage groupings.
Analysis of Each Blastomere of Entire Embryos 
Blastomeres o f cleavage stage embryos were separated and assayed individually 
to provide information on the variability of telomerase activity from one cell to the next 
within an entire embryo. Twenty-three donated or deselect embryos were evaluated from 
11 patients. The embryos ranged from 2-cell to 14-cell with 2 single (8.7%), 7 normal 
(30.4%), and 14 (60.9%) multi-pronuclear in development. One hundred forty-three
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blastomeres were isolated and evaluated from these 23 embryos. During isolation, 28 
(19.7%) of the individual blastomeres lysed. O f the 143 blastomeres evaluated, 24 had 
no measurable telomerase activity and one sample was lost due to technical difficulty. 
Twelve (52.2%) of the 23 embryos had at least one cell that did not express telomerase
activity.
Variance analysis of the blastomere TPG levels and RTA levels showed no 
difference in the method to evaluate telomerase activity, but did find that 18% of the 
variance was the result of different embryos and 82% of the variability is the result of 
differences in blastomeres.
Telomerase Activity as Predictor of Blastocyst Development 
This experiment utilized frozen 2-pronuclear embryos donated by 33 IVF couples. 
One hundred sixty-two embryos were thawed. Of those 162 thawed, 142 (88%) survived 
and 123 (79%) cleaved following 24 hours incubation. Eighty-eight reached the 
appropriate stage for biopsy. One to 2 cells were removed from each biopsied embryo 
and the cells were assayed individually, resulting in 133 blastomeres biopsied from 88 
embryos. Four blastomeres were lost during the biopsy procedure, resulting in the loss of 
information on two embryos biopsied. In addition to the 88 embryos biopsied, 5 embryos 
were unable to be biopsied due to premature morulation. Of the 162 embryos thawed for 
this study, 43 (26.5%) progressed to the blastocyst stage. The blastocyst rate related to 
embryos that were biopsied was 39 blastocysts o f 88 embryos biopsied or 44.3%.
Nuclear status was evaluated in each blastomere and 23% had no visible nucleus, 73% 
had one nucleus and 4% had 2 nuclei. Lysis or partial lysis o f the blastomere biopsied 
occurred in 18% of blastomeres biopsied. Technical difficulties with the TRAP assay
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resulted in the loss o f blastomere data from 11 biopsied embryos, which resulted in a 
remaining 75 embryos that could be evaluated. The primer used with these samples 
appeared to be lacking the fluorescent label necessary to evaluate the bands on the gel.
Both methods were used to calculate telomerase activity and the results were not 
different using TPG or RTA (Table 1). The average cell number at biopsy for the 
arrested group was 5.78 (±1.2) compared to the blastocyst group with 7.13 (±0.92) cells. 
Telomerase activity was compared between embryos biopsied that arrested and embryos 
biopsied that progressed to blastocyst. There were two methods used to provide the TPG 
or RTA value for an embryo, when there were 2 cells biopsied. The first method was to 
average the two values and the second method was to choose the higher value of the two 
to represent that embryos activity. No statistical differences were noted between the two 
groups of biopsied embryos when either the averaging or higher value method was 
analyzed.
TABLE 1. Telomerase activity in blastomeres biopsied from 75 day 3 embryos and 
evaluated for blastocyst growth
TPG Units RTA Units
Embrvos Average Highest Average Highest
Arrested 42 11.4 ± 4 12.8 ± 4 0.16 ±0.08 0.18 ±0.08
Blastocyst 33 10.3 ±5 12.6 ± 6 0.13 ±0.06 0.16 ±0.06
The final segment o f this study involved the isolation and analysis of telomerase 
activity in the inner cell masses of the blastocysts that developed. Forty blastocysts were
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treated to immunosurgery, but technical difficulties with the procedure resulted in the 
inability to treat 9 blastocysts. Six (19.4%) o f the blastocysts treated did not have an 
identifiable ICM. The ICM sized ranged from 20 to 150 pm. Each ICM was analyzed in 
whole for the telomerase assay. During the TRAP procedure an additional 18 ICM 
experienced technical difficulties related to the primer problem discussed in the earlier 
experiment. Nevertheless, a comparison of ICM size verses TPG or RTA value for the 
biopsied biastomere(s) associated with 13 blastocysts was conducted. No statistical 
relationship could be identified between ICM size and blastomere TPG or RTA. Nine 
ICM did undergo the TRAP assay successfully and the data is presented in Fig. 5 and Fig. 
6. The telomerase activity detected in these ICM did not statistically differ from that of 
the whole blastocyst.




With development o f the polymerase chain reaction (PCR) - based Telomeric 
Repeat Amplification Protocol (TRAP) by Kim et al. (1994), researchers have initiated a 
broader understanding of the mechanisms involved in extension o f the chromosomal 
telomeric ends. This original protocol has been modified in numerous ways to improve 
the speed and sensitivity. This laboratory is utilizing a modified version of TRAP, which 
is available in a kit form (TRAPeze®, Intergen Inc.), decreasing the time needed to 
prepare and test reagents. Another modification was incorporated into the TRAPeze® 
system to increase the quantifying sensitivity in this laboratory. The substrate primer 
(TS) was labeled with an infrared fluorochrome, necessary for using the IR2 DNA 
sequencing system (LI-COR).
The purpose of this study was to 1) modify the current TRAP method to analyze 
telomerase activity for the whole embryo and the single cell o f an embryo, 2) use this 
method to study the trends in expression of telomerase activity in whole oocytes through 
blastocyst development and finally, 3) establish if the telomerase activity measured in a 
blastomere of a day 3 embryo can be used to predict blastocyst development.
Since the TRAPeze® kit was modified in use from the manual provided, some 
preliminary testing was necessary to verify accuracy of results. Evaluation of two cell 
lines from two different species was the first assay conducted to measure telomerase 
activity and was detected in the human (DU-145) and the mouse (PMEF) cell types using 
the TRAP assay that was modified in this laboratory. Two other human cell types, Hs27 
and Detroit 551, were analyzed for telomerase activity and none was detected. Hs27,
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newborn foreskin, was previously shown to lack telomerase activity by Bodnar et al. 
(1998). The fact that the Detroit 551 cell line, female embryonic skin, did not express 
telomerase activity was not unexpected due to the cell type having a finite number o f 
subcultures, suggesting the cells are terminally differentiated. To establish the range of 
the assay after the modifications incorporated, an initial study was conducted using 
dilutions o f the positive control cell lysate. The lysate was diluted from 10,000 to 1 cell 
equivalents and a correlating trend was noted in telomerase activity, being lowest in the 
1-cell equivalent and highest in the 10,000-cell equivalent. Finally, 60 individual cells 
were isolated from the human carcinoma cell line, DU-145, and each cell analyzed 
individually. This experiment would more closely replicate the use o f the assay for 
evaluating biopsied cells of embryos. Telomerase activity was detected in each cell 
analyzed. This entire series of preliminary experiments established the initiation of a 
successful TRAP assay system for evaluating telomerase activity in human oocytes and 
preimplantation embryos.
Very little data, previous to this study, on human oocytes and embryos had been 
published. Wright et al. (1996) studied a few samples of mature oocytes, sperm, and 
blastocysts that were discard material from IVF cycles. No telomerase activity was 
detected in the mature sperm or oocytes, but very high levels were measured in the 
blastocysts evaluated. In the study conducted in our laboratory, whole oocytes and 
embryos were tested for telomerase activity after removing the zona pellucida. Each 
oocyte or embryo was analyzed individually and 97 6% of the samples evaluated had 
detectable levels of telomerase. Immature oocytes and blastocysts expressed the highest 
levels and were greater than zygotes or any of the cleavage stage groupings.
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Interestingly, there was no difference between the levels detected in the immature oocyte 
and the blastocyst with approximately 65 cells (Devreker et al., 1998). This high level of 
telomerase activity in the single cell immature oocyte suggests a possible role for 
telomerase in meiosis (Betts and King, 1999). Two studies in other species, bovine 
(Betts and King, 1999) and rat (Eisenhauer et al., 1997), found measurable levels of 
telomerase activity in the mature oocyte, albeit low. The high level of expression of 
telomerase in the immature oocyte was also seen in the bovine (Betts and King, 1999) 
and in the rat (Eisenhauer et al., 1997). Although similar trends were seen in the data 
from this study, both the bovine and rat studies utilized pooled samples of their oocytes 
and embryos for TRAP analysis, which differs from this laboratory’s method of 
individual analysis. The authors of the bovine and rat studies also used different methods 
to calculate telomerase activity. The bovine study used the relative telomerase activity 
(RT A) method using a positive control cell line as the method to normalize data. The 
Eisenhauer et al. (1997) rat study used a similar calculation method, but expressed the 
value on a per cell basis as the percentage relative to a positive cell (293 cells) assayed in 
parallel. However, the same trends were seen in expression o f telomerase activity in the 
oocyte and embryo.
When the data for whole oocytes and embryos were evaluated on a per cell basis, 
telomerase declined from the immature oocyte through maturation and fertilization and 
leveled off to a similar value per cell through subsequent cleavages. The immature 
oocyte has a much larger cytoplasmic volume than cells from subsequent divisions and 
this is certainly part o f the reason for the significantly higher levels of telomerase 
activity. However, the mature oocyte has a similar volume as the immature oocyte with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
42
an apparent decline in telomerase activity and this trend continues through the one cell 
zygote. Perhaps this decline in telomerase activity is due to depletion of the maternal 
stores o f proteins known to exist in the oocyte. As the shift from oocyte to embryonic 
genome takes places at approximately the 4-cell stage (Braude et al., 1988) there is an 
upregulation of critical proteins. Analysis of this data on a per cell basis does not show 
an upregulation of telomerase activity.
Results showed a significant level of variability from one cell to the next within 
an embryo. Certainly, it has been well established that cells within an embryo may be 
different. Several authors have published on the high incidence of mosacism of normal 
and abnormal embryos (Munne et al., 1993; DeScisciolo et al., 2000). Results here show 
that, in this population of embryos evaluated, 18% o f the variance of blastomere TPG 
units is the result of different embryos and 82% of the variance is due to differences 
between the blastomeres.
Human embryo biopsy has become a standard of care for certain couples trying to 
avoid genetic disease in their offspring. Research has shown that there is no detrimental 
affect to the embryo by removing 1 or 2 cells from the day 3 embryo (Hardy et al., 1990). 
There are no publications that refer to the use of thawed pronuclear embryos cultured to 
day 3, biopsied, and followed to the blastocyst stage or the evaluation of telomerase 
activity within these blastomeres. A 44% blastocyst rate was achieved with these 
thawed, cultured, and biopsied embryos. This study’s blastocyst rate is lower than the 
average reported by Hardy et al. (1990) o f 71% blastocyst rate from biopsied embryos. 
Some differences in the study by Hardy et al. (1990) is their use o f fresh embryos and 
they only reported on the biopsy of embryos that reached the 8-cell stage. Our laboratory
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biopsied embryos when they reached the 5 to 9-cell stage.
Telomerase levels were not statistically different for biopsied blastomeres 
evaluated from the embryos that arrested in development and those that progressed to 
blastocyst. Variability of measurable telomerase activity undoubtedly played a role in the 
inability to distinguish differences between the two groups. These results suggest that 
telomerase activity in the day 3, biopsy stage embryo, is not a predictor of blastocyst 
development potential.
This is the first study to evaluate telomerase activity o f ICM isolated from the 
trophoblast cells of the whole blastocyst. Nineteen percent o f blastocysts evaluated did 
not contain an ICM. Yet, all ICM analyzed had detectable levels of telomerase activity 
that were not significantly different from the whole blastocyst. This data suggests that a 
significant level of telomerase activity o f the whole blastocyst is originating from the 
ICM, when one recognizes that the ICM only constitutes approximately 30% o f the cell 
number associated with the blastocyst (Devreker et al., 1998).
The results of this study leads researchers into new territory for study o f the 
human oocyte and preimplantation embiyo. Evaluation o f telomerase levels within the 
immature oocyte in the future could provide some beneficial information on the role of 
telomerase and aneuploidy that is present at a higher level in older oocytes.
Measurement of the telomeric length o f the immature oocytes o f older verses younger 
patients might show evidence of shortening telomeric length, predisposing the older 
oocyte to inappropriate divisions leading to aneuploidy.
Culture systems for the human preimplantation embryo are constantly evolving. 
Research in the mouse (O’Neill, 1997; O’Neill, 1998) has found a beneficial effect of
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growing groups of mouse embryos within microdrops. These mouse embryos appeared 
to require certain autocrine signals to survive through the 2-cell stage and progress in 
growth. Future studies in the human need to address the role o f autocrine factors on 
embryo development. Studies could be designed to address whether various culture 
systems currently employed inhibit or enhance the embryonic genome’s ability to express 
telomerase activity.
In summary, this is the first study that evaluated the level of telomerase activity in 
discard material of whole oocytes through blastocysts, finding that all stages expressed 
telomerase activity. Immature oocytes and blastocysts had the highest levels o f 
telomerase activity and were significantly greater than the levels from zygote through 
pre-morula stages. Variability within cells o f an embryo was found to be very high. 
Telomerase activity measured in 1 to 2 cells biopsied, from day 3 cleaving embryos, did 
not predict the potential for development to blastocyst stage.
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